Small Cap Feast
Small Cap Feast – 08 April 2019
Set Menu AIM:
Total number of AIM Companies (Incl Susp): 898
Total number of AIM Companies trading: 827*
* As at 03 May 2019
Set Menu NEX Growth:
Total number of NEX Growth Market Companies (Incl Susp): 89*
Total number of NEX Growth Market Companies trading: 87*
* As at 03 May 2019
Set Menu Standard List:
Total number of Standard List Companies (Incl Susp): 161*
Total number of Standard List Companies trading: 141*
* As at 03 May 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Main Market (Premium)
Jewel UK Midco Limited, the parent company of The Watches of Switzerland Group Limited, is looking to join the premium segment of the main market. Offer TBC, expect TBC
Finablr plc— global platform which provides Cross-Border Payments and Consumer Solutions, Consumer Foreign Exchange Solutions and B2B and Payment Technology Solutions to consumers and businesses in the large and growing payments and foreign exchange market is looking to list on the Main Market plans to raise $200m, expected May 2019
Main Market (Standard)
IMC Exploration Group (NEX: IMCP), focused on acquiring and exploring prospecting licence areas which have high potential for natural resource, is looking to admit its shares to the standard list and will withdraw for the NEX Exchange. Expected 11 June 2019
Induction Healthcare Group plc—a healthcare technology company focused on streamlining the delivery of care by Healthcare Professionals looking to join AIM. Expected raise of £14.58m at 115p, market cap of £34.07m. Expected 22 May 2019.
SDX Energy plc—a North Africa focused oil and gas company, announces its intention to complete a Canadian plan of arrangement under section 192 of the Canada Business Corporations Act and will have shares de-listed from the TSX-V and admitted to trading on AIM. Expected 28 May 2019, anticipated market cap of £76m
Renold plc—a leading international supplier of industrial chains and related power transmission products, announced that it will cancel the listing of the Company from the premium segment and apply for admission on AIM. Expected 06 June 2019.
Distribution Finance Capital Holdings plc — specialist lender which builds relationships with manufacturers and then provides working capital solutions up and down their supply chains to drive their growth is looking to join AIM. No raise, secondary offering of £19.8m at 90p, expected market cap of £95.98m. Expected 09 May 2019.
Alumasc Group plc, the premium building products, systems and solutions group, has announced its intention to move from the Premium Segment of the main market to AIM. Expected market cap of £33.4m. Expected 25 June 2019
Arbuthnot Banking Group plc, primarily involved in banking and financial services including commercial banking, private banking, wealth planning and investment management, is looking to joining the NEX Exchange Growth Market. Expected 17 May 2019
Smartspace Software (SMRT.L) 86p £19.06m
The provider of ‘Integrated Space Management Software’ for smart buildings, commercial spaces and hospitality, announced its unaudited final results for FYJan19
Revenue from continuing operations up 2.8% to £6.3m
Adjusted LBITDA £2.66m (FY18: EBITDA: £0.2m)
Loss before tax from continuing operations of £4.2m (FY18: loss £0.7m)
Profit from disposal of subsidiaries £2.95m
Net cash position at 31 Jan 2019 £7.6m (FY18: £1.2m)
“Our plan in the coming year is to continue to invest into sales and marketing to enterprise and mid-market companies to maximise the opportunity we see for workplace technology, both in the UK and overseas. This sales and marketing effort will also include further development of channel sales opportunities. During the coming year we expect to see increased sales from partners, in particular via Evoko, who operate through 400 resellers and distributors across the globe.”
Reneuron (RENE.L) 283.5p £97.52m
The specialist in the development of cell-based therapeutics, announced a year-end business update ahead of its preliminary results for the year ended 31 Mar 2019, which will be announced on 11 July 2019.
Significant progress advancing the clinical development of the Company’s human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP). Most recently, on 26 April 2019, the Company reported positive preliminary data in the first cohort of the Phase 2a part of its study of hRPC in RP.
Continuing to progress the clinical development of its CTX cell therapy candidate for stroke disability. In Jan 2019, the Company announced that patient dosing had commenced in PISCES III, a randomised, placebo-controlled, Phase 2b clinical trial in 110 patients at up to 40 clinical trial sites in the US.
Financial results for the year ended 31 Mar 2019 remain in line with the Board’s previous expectations. The Company had unaudited cash, cash equivalents and bank deposits totalling £26.39m
MaxCyte (MXCT.L) 177p £103.4m
MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform
No dose-limiting toxicities or safety concerns observed in first cohort of treated patients
Feasibility of streamlined, faster CAR therapy manufacturing process confirmed
Dosing initiated in second cohort of patients
“We are very excited about the potential of MCY-M11 as a new, effective therapeutic in solid tumours where the majority of patients still have very limited treatment options.”
The manufacturing process for MCY-M11 utilizes MaxCyte’s proprietary Flow Electroporation® technology to transfect mRNA into fresh (i.e., unexpanded) peripheral blood mononuclear cells (PBMCs). This streamlined, faster manufacturing process for an autologous cell therapy is an important differentiator from other CAR technologies
Cello Health (CLL.L) 132.5p £138.3m
AGM statement from the global healthcare-focused advisory Group.
“The Group has had a very good start to the year. For the first quarter, the Group has experienced good like-for-like net revenue and headline PBT growth. We are also confident regarding performance in the second quarter, and expect to report robust headline profit before tax growth for the first half of the year.
“At a segment operating level, Cello Health has had an excellent first quarter. In particular, the performances in our consulting businesses and in the US overall are notable. We expect the second quarter to continue this trend.
“Cello Signal has also made a solid start to the year in line with expectations.
“The Group’s balance sheet remains strong, with better than expected cash conversion so far in 2019, continuing the strong cash conversion performance delivered in 2018. The Group continues to assess suitable acquisitive growth opportunities in the US.
“The Board is therefore confident of achieving a successful full year result in 2019, in line with expectations.”
Johnson Services (JSG.L) 149p £549.63m
The leading UK textile services provider, will be holding its AGM today and Chairman, Bill Shannon, will make the following statement:
“Following a year of continued growth, the performance of both the Workwear and HORECA Divisions has continued to meet management forecasts. Accordingly, we expect the full year results to be in line with current market expectations.
“The development of the new Leeds high volume linen facility, which will deliver considerable logistical benefits and increased capacity for our business in Northern England, is proceeding to plan and remains on course for coming on stream in the spring of 2020.”
Altus Strategies (ALS.L) 4.25p £7.38m
The Africa focused project and royalty generator, announced that on 07 May 2019 it signed a Variation and Accession Deed with Resolute Mining Ltd in respect of the joint venture on the Company’s 106km2 Pitiangoma Est project in southern Mali. T he Project is located approximately 15km south of the Tabakoroni mine and 40km south of the Syama gold mine, both owned and operated by Resolute.
JV with Resolute in southern Mali extended by two years to May 2021
Resolute to earn an initial 70% interest by funding $3m in exploration and by completing a feasibility study
Altus retains option to co-fund its 30% interest on a pro rata basis or exchange its interest for a 2% Net Smelter Return royalty
Drilling by Resolute is currently underway at the Pitiangoma Est project
Online Blockchain (OBC.L) 20.5p £1.73m
As previously announced, Online Blockchain, a UK blockchain company, has been developing new blockchain-based products and in April 2019 announced the launch of “invite-only” beta testing for FreeLoadr, a PC gaming product. The Company has launched today the beta testing of an additional product, FreeFaucet (www.freefaucet.io), which enables users to obtain established and emerging cryptocurrencies for free. Users’ cryptocurrencies can then be stored on the FreeFaucet multi-coin wallet.
Shareholders should note that the development of FreeFaucet is in early beta testing stage of development and launch, and further updates will be provided in due course.
PCI-PAL (PCIP.L) 20.5p £8.30m
The secure payments provider to contact centres, announces that it has now deployed live customer cloud services on all of its Amazon Web Services (“AWS”) instances, including beyond its core markets of the U.K. and U.S. These new additional AWS instances are located in Canada, Australia, and Germany.
With 100% cloud provisioning and no hardware requirements, customer deployments in any country or region are not only practical to deliver but also cost-effective for both our partners and customers alike. No on-site deployment services are required as all technical and professional services can be performed remotely. This is of particular value to an increasing number of our partners who prefer to project manage customer deployments themselves.
NQ Minerals (NEX:NQMI) 5p £16.2m
April 2019 and Year to Date (YTD) production results from its flagship Hellyer Mine located in Tasmania. All numbers in Dry Metric Tonnes.
Apr 2,145 Q1 4,712 YTD 6,857
Apr 1,748 Q1 3,015 YTD 4,763
Apr 10,901 Q1 18,488 YTD 29,389
The month of April has been a record month for production and sales. Operational efficiencies continue to be realised with month over month improvements in dredged and milled tonnes.
EMIS Group (EMIS.L) 1,154p £730m
AGM Statement. “The Board of EMIS Group, the UK leader in connected healthcare software and services, announced that trading for the year to date is in line with the Board’s expectations. As reported on 20 March 2019 at the time of its 2018 Full Year Results, the Group continues to have market-leading positions, high levels of recurring revenue and remains in a strong financial position.”
Highlights the recent disposal of the non-core Specialist & Care business representing an important step towards focusing the Group on its medium-term growth plan. To support the realigned business, the Group is deploying improved internal systems, which are expected to drive greater efficiencies during 2019 and beyond.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.